Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors (Q33412724)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24434430%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24434430%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24434430%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Thomas Mühlenberg

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24434430%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

James Nagarajah

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24434430%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

R A Hilger

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24434430%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

F Grabellus

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24434430%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

M Hoiczyk

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24434430%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

A Reichardt

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24434430%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

M Ahrens

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24434430%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

P Reichardt

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24434430%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

S Grunewald

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24434430%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

M E Scheulen

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24434430%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

A Pustowka

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24434430%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

E Bock

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24434430%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

M Schuler

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24434430%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

D Pink

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24434430%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

language of work or name

English

0 references

publication date

16 January 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24434430%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

5 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24434430%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

110

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24434430%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24434430%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

1155-1162

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24434430%20AND%20SRC:MED&resulttype=core&format=json

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

5 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3950855

Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3950855

Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3950855

Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3950855

Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3950855

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3950855

A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3950855

Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3950855

High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3950855

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3950855

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3950855

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3950855

Histone deacetylase inhibitors: molecular mechanisms of action

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3950855

Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3950855

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3950855

Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3950855

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3950855

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3950855

Clinical pharmacokinetics of imatinib

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3950855

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3950855

Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3950855

PDGFRA activating mutations in gastrointestinal stromal tumors.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3950855

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3950855

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3950855

Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2013.826

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2013.826

KIT activation is a ubiquitous feature of gastrointestinal stromal tumors

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3950855

31 October 2018

Identifiers

DOI

10.1038/BJC.2013.826

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24434430%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

5 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24434430%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

PubMed publication ID

24434430

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24434430%20AND%20SRC:MED&resulttype=core&format=json